1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Global Gastric Cancer Drugs Market 2016-2020

Global Gastric Cancer Drugs Market 2016-2020

  • December 2015
  • -
  • Infiniti Research Limited
  • -
  • 99 pages

Market outlook of the global gastric cancer drugs market
Technavio’s market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market’s healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period.

The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer.

Geographical segmentation and analysis of the gastric cancer drugs market
- Americas
- APAC
- Europe

In this market study, analysts have estimated the APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.


Competitive landscape and key vendors
The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.


The top vendors in the market are -
- Hoffmann-La Roche
- Eli-lilly
- Sanofi
- Otsuka Holdings

Other prominent vendors in the market include Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.


Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global gastric cancer drugs market?
- What are the key market trends impacting the growth of the gastric cancer drugs market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the vendors in the global gastric cancer drugs market?
- Trending factors influencing the market shares of the Americas, APAC, and Europe?
- What are the key outcomes of the five forces analysis of the gastric cancer drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related report:
- Global Colorectal Cancer Drugs Market 2015-2019
- Global Colorectal Cancer Drugs Market 2015-2019
- Global Cancer Pain Therapeutics Market 2015-2019

Table Of Contents

Global Gastric Cancer Drugs Market 2016-2020
PART 01: Executive summary
- Highlights
- PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- PART 03: Market research methodology
- Research methodology
- Economic indicators
- PART 04: Introduction
- PART 05: Disease overview
- Understanding the disease
- Pathophysiology
- Causes
- Signs and symptoms
- Diagnosis
- Staging
- Japanese staging system
- Treatment
- Epidemiology
- Economic burden
- PART 06: Pipeline portfolio
- Information on pipeline candidates
- PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
- PART 08: Market segmentation by molecule type
- Small molecules
- Biologics
- PART 09: Market segmentation by route of administration
- Oral
- Parenteral
- PART 10: Market segmentation by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy
- PART 11: Geographical segmentation
- Global gastric cancer drugs market by geographical segmentation 2015-2020
- Gastric cancer drugs market in APAC
- Gastric cancer drugs market in Japan
- Gastric cancer drugs market in China
- Gastric cancer drugs market in Americas
- Gastric cancer drugs market in EMEA
- PART 12: Market drivers
- Promising drug pipeline
- Unmet medical needs
- Increase in patient population
- Patient assistance programs
PART 13: Impact of drivers
PART 14: Market challenges
- High cost of drugs
- Adverse side effects
- Shortage of drugs
- Delayed diagnosis
PART 15: Impact of drivers and challenges
PART 16: Market trends
- Rise in public awareness
- Use of off-label drugs
- Intense competition among vendors
PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2015
- Eli Lilly
PART 18: Key vendor analysis
- Eli Lilly
- F. Hoffmann-La Roche
- Otsuka Holdings
- Sanofi
- Other prominent vendors
PART 19: Appendix
- List of abbreviation
PART 20: Explore Technavio
?




Exhibit 01: Product offerings 9
Exhibit 02: Types of gastric cancer
Exhibit 03: Frequency of different types of gastric cancers
Exhibit 04: Causes of gastric cancer
Exhibit 05: Signs and symptoms of gastric cancer
Exhibit 06: Diagnostic tests for gastric cancer
Exhibit 07: Staging of gastric cancer
Exhibit 08: Treatment options for gastric cancer
Exhibit 09: First-line therapy for metastatic or locally advanced gastric cancer
Exhibit 10: Second-line therapy for gastric cancer
Exhibit 11: Surgeries for gastric cancer
Exhibit 12: Types of radiation therapy for gastric cancer
Exhibit 13: Estimated number of new cancers (all ages) males and females in Americas, EMEA, and APAC: 2015 and 2020
Exhibit 14: Estimated number of new cancers (age =65) males and females in Americas, EMEA, and APAC: 2015
Exhibit 15: Estimated number of mortality cases (all ages) males and females in Americas, EMEA, and APAC: 2015
Exhibit 16: Estimated number of mortality cases (age =65) males and females in Americas, EMEA, and APAC: 2015
Exhibit 17: Pipeline molecules for gastric cancer
Exhibit 18: Gastric cancer clinical trials by development phase
Exhibit 19: Gastric cancer clinical trials by trial status
Exhibit 20: Global gastric cancer drugs market 2015-2020 ($ millions)
Exhibit 21: Five forces analysis
Exhibit 22: Global gastric cancer drugs market segmented by molecule type
Exhibit 23: Global gastric cancer drugs market segmented by route of administration
Exhibit 24: Dose and administration schedule of Teysuno (S-1) plus cisplatin
Exhibit 25: Lines of therapy for the treatment of advanced gastric cancer
Exhibit 26: Estimated annual cost per patient for chemotherapy regimen in EU ($ millions)
Exhibit 27: Global gastric cancer drugs market by geographical segmentation 2015
Exhibit 28: Global gastric cancer drugs market region wise 2015-2020 ($ millions)
Exhibit 29: Gastric cancer drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Gastric cancer drugs market in Japan 2015-2020 ($ millions)
Exhibit 31: Gastric cancer drugs market in China 2015-2020 ($ millions)
Exhibit 32: Gastric cancer drugs market in Japan and China 2015-2020 ($ millions)
Exhibit 33: Gastric cancer drugs market in Americas 2015-2020 ($ millions)
Exhibit 34: Gastric cancer drugs market in EMEA 2015-2020 ($ millions)
Exhibit 35: Key drivers for global gastric cancer drugs market
Exhibit 36: Number of patients treated with Herceptin via Patient Assistance Program in China
Exhibit 37: Impact of drivers
Exhibit 38: Challenges of global gastric cancer drugs market
Exhibit 39: Average cost comparison of Herceptin
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Trends of global gastric cancer drugs market
Exhibit 42: Timeline of Cyramza in US, EU, and Japan
Exhibit 43: Eli Lilly: Key takeaways
Exhibit 44: Timeline of Herceptin in US, EU, and Japan
Exhibit 45: F. Hoffmann-La Roche: Global YoY growth and revenue of Herceptin 2011-2014 ($ millions)
Exhibit 46: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ millions)
Exhibit 47: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ millions)
Exhibit 48: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
Exhibit 49: F. Hoffmann-La Roche: Key takeaways
Exhibit 50: Timeline of Tegafur in Japan, EU, and Asia
Exhibit 51: Otsuka Holdings: Key takeaways
Exhibit 52: Timeline of Taxotere in US, EU, and Japan
Exhibit 53: Sanofi: Global YoY growth and revenue of Taxotere 2011-2014 ($ millions)
Exhibit 54: Sanofi: YoY growth and revenue of Taxotere in US 2011-2014 ($ millions)
Exhibit 55: Sanofi: YoY growth and revenue of Taxotere in EU 2011-2014 ($ millions)
Exhibit 56: Sanofi: Key takeaways
Exhibit 57: Eli Lilly: Business segmentation by revenue 2014
Exhibit 58: Eli Lily: Business/Product segmentation by revenue 2012 and 2013 ($ millions)
Exhibit 59: Eli Lily: Geographical segmentation by revenue 2014
Exhibit 60: F. Hoffmann-La Roche: Business segmentation by revenue 2014
Exhibit 61: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 62: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 63: Otsuka Holdings: Business segmentation 2014 by revenue
Exhibit 64: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 65: Otsuka Holdings: Geographical segmentation by revenue 2014
Exhibit 66: Sanofi: Business segmentation by revenue 2014
Exhibit 67: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 68: Sanofi: Geographical segmentation by revenue 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...

Gastric Cancer  - Market Insights, Epidemiology and Market Forecast-2023

Gastric Cancer  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Gastric Cancer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Gastric Cancer Treatment Market - Growth, Trends and Forecasts (2016 - 2021)

Global Gastric Cancer Treatment Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global gastric cancer therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry in Nigeria

  • November 2016
    8 pages
  • Cancer  

    Cancer  

  • Nigeria  

    Africa  

View report >

Digestive System Disorder Statistics in the US

  • October 2016
    11 pages
  • Digestive Syste...  

  • United States  

    United Kingdom  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Related Market Segments :

Gastric Cancer
Therapy
Chemotherapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.